COMP <GO>
INDV vs ARQT // NET PROFIT MARGIN
Indivior Pharmaceuticals Inc. (NASDAQ) VS. Arcutis Biotherapeutics Inc. (NASDAQ) • 15-METRIC TALLY: INDV 6
— ARQT 6
▲ NET PROFIT MARGIN LEADER: INDV
LAST: $35.37 (+0.34%) • MKT CAP: $4.17B
net-margins
16.90%
LAST: $32.07 (+0.31%) • MKT CAP: $4.03B
net-margins
-4.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INDV VS. ARQT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INDV | ARQT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 80.20% | 90.20% | -10.00 | ARQT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 62.20% | -3.00% | +65.20 | INDV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 13.4x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.24% | -0.16% | -2.08 | ARQT | /fcf-yield <GO> |
| Operating Margin | 21.10% | -3.30% | +24.40 | INDV | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 16.90% | -4.30% | +21.20 | INDV | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | 91.30% | -87.00 | ARQT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.13 | 7.78 | -4.65 | ARQT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 6/9 | -1.00 | ARQT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.3 | 66.0 | -13.70 | ARQT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.00 | +0.15 | INDV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.4x | 24.0x | -5.60 | INDV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.17B | $4.03B | $144.0M | INDV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INDV REV | ARQT REV | INDV GROSS % | ARQT GROSS % | INDV FCF | ARQT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.24B | $376.1M | 80.2% | 90.2% | -$93.0M | -$6.3M |
| FY 2024 | $1.19B | $196.5M | 80.6% | 90.3% | $7.0M | -$112.3M |
| FY 2023 | $1.09B | $59.6M | — | — | -$349.2M | -$249.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INDV // BETA 1.15
ARQT // BETA 1.00